BPDCN

BPDCN and Leukemia: What’s the Difference?
November 22, 2022

Blastic plasmacytoid dendritic neoplasm is commonly misdiagnosed as various forms of leukemia.

POLL: Have You Ever Treated Blastic Plasmacytoid Dendritic Cell Neoplasm?
November 07, 2022

Click here to answer this week's poll.

The Weekly Roundup: October 31-November 4
November 04, 2022

ICYMI, this week we had stories about blastic plasmacytoid dendritic cell neoplasm, epidermolysis bullosa, an interview with Seth Matarasso, MD, and more.

BPDCN: More Than Just a Rash
November 02, 2022

Blastic plasmacytoid dendritis cell neoplasm is a rare and aggressive form of cancer that usually makes its appearance in the form of red to violet papules and plaques.

Clinical Research Updates for Treating Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
October 21, 2022

An expert weighs in on the latest updates in clinical research about this rare blood cancer that often manifests with cutaneous lesions.

Leading Blastic Plasmacytoid Dendritic Cell Neoplasm Expert Perspective: Use Social Media for Breaking Research and Networking with Other BPDCN Experts
October 21, 2022

A world leader in BPDCN explains how using social media can enhance dermatologists’ knowledge about this rare form of aggressive blood cancer.

Diagnosis, management challenging for pediatric BPDCN
October 03, 2022

A 13-year-old boy presenting an asymptotic dark violaceous infiltrated nodular lesion located on the left cheek was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often presents with skin manifestations.

BPDCN patients at increased risk of second primary malignancies
September 29, 2022

Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

Target therapies under study to treat BPDCN
December 08, 2020

Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632.